[go: up one dir, main page]

MX2018015960A - Stable liquid pharmaceutical preparation. - Google Patents

Stable liquid pharmaceutical preparation.

Info

Publication number
MX2018015960A
MX2018015960A MX2018015960A MX2018015960A MX2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
liquid pharmaceutical
stable liquid
antibody
preparation according
Prior art date
Application number
MX2018015960A
Other languages
Spanish (es)
Inventor
Young Kim So
Won Lee Joon
Yong Han Won
Jung Kim Su
Seok Oh Jun
Hyeon Hong Su
Kyeong Shin Yeon
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015960(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MX2018015960A publication Critical patent/MX2018015960A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

A stable liquid pharmaceutical preparation according to the present invention contains: an antibody or an antigen-binding fragment thereof; a surfactant; a sugar or a derivative thereof; and a buffer. The stable liquid pharmaceutical preparation according to the present invention has low viscosity while containing a high amount of the antibody, has excellent long-term storage stability on the basis of excellent stability under accelerated conditions and extreme conditions, and can be administered subcutaneously.
MX2018015960A 2016-06-30 2017-06-28 Stable liquid pharmaceutical preparation. MX2018015960A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30
PCT/KR2017/006855 WO2018004260A1 (en) 2016-06-30 2017-06-28 Stable liquid pharmaceutical preparation

Publications (1)

Publication Number Publication Date
MX2018015960A true MX2018015960A (en) 2019-03-21

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015960A MX2018015960A (en) 2016-06-30 2017-06-28 Stable liquid pharmaceutical preparation.

Country Status (40)

Country Link
US (3) US11951207B2 (en)
EP (2) EP3479819B1 (en)
JP (2) JP7082070B2 (en)
KR (3) KR20180003452A (en)
CN (1) CN109310628A (en)
AU (2) AU2017287743C1 (en)
CA (1) CA3028238C (en)
CL (1) CL2018003662A1 (en)
CO (1) CO2018013689A2 (en)
CR (1) CR20180599A (en)
CU (1) CU24561B1 (en)
DK (1) DK3479819T5 (en)
DO (1) DOP2018000290A (en)
EA (1) EA201892653A1 (en)
EC (1) ECSP18093651A (en)
ES (1) ES2975782T3 (en)
FI (1) FI3479819T3 (en)
GE (1) GEP20217249B (en)
HR (1) HRP20240426T1 (en)
HU (1) HUE066142T2 (en)
IL (1) IL263630B2 (en)
JO (1) JOP20180125B1 (en)
LT (1) LT3479819T (en)
MA (1) MA45562B1 (en)
MD (1) MD3479819T2 (en)
MX (1) MX2018015960A (en)
NI (1) NI201800139A (en)
PE (1) PE20190448A1 (en)
PH (1) PH12018502670B1 (en)
PL (1) PL3479819T3 (en)
PT (1) PT3479819T (en)
RS (1) RS65395B1 (en)
SG (1) SG11201811320YA (en)
SI (1) SI3479819T1 (en)
SM (1) SMT202400143T1 (en)
TN (1) TN2018000443A1 (en)
TW (1) TWI736643B (en)
UA (1) UA122610C2 (en)
WO (1) WO2018004260A1 (en)
ZA (1) ZA201808476B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
KR20190024572A (en) * 2017-08-30 2019-03-08 (주)셀트리온 Subcutaneous Dose Regimen For Treating TNFα-related Disorders
WO2020060192A1 (en) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Trastuzumab stabilizing liquid formulation containing high concentration of surfactant
JP7374544B2 (en) * 2018-10-10 2023-11-07 アステラス製薬株式会社 Pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment complex
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
AR118191A1 (en) * 2019-02-28 2021-09-22 Celltrion Inc METHODS FOR THE TREATMENT OF TNFa-RELATED DISEASES
CN111686247B (en) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 Liquid composition comprising antibody to human interleukin-4 receptor alpha
WO2020187760A1 (en) * 2019-03-18 2020-09-24 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
WO2020219681A1 (en) * 2019-04-23 2020-10-29 Sanofi Anti-cd38 antibodies and formulations
CN110095615A (en) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 A kind of kit measuring hs-CRP content
CN110585430B (en) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 Pharmaceutical composition of humanized anti-human IL-17A monoclonal antibody
CA3169901A1 (en) * 2020-03-13 2021-09-16 Mi Gyeong Kim Pharmaceutical liquid composition having increased stability
JP7560038B2 (en) * 2020-04-06 2024-10-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody preparations
CA3183934A1 (en) * 2020-05-29 2021-12-02 Amgen Inc. Antibody formulations and uses thereof
CN114099424B (en) * 2020-08-25 2025-03-14 越海百奥药业(绍兴)有限公司 A preparation of recombinant immune cytokine
KR20240073051A (en) * 2021-09-16 2024-05-24 주식회사 에이프로젠 Pharmaceutical compositions comprising anti-TNFα antibodies
CN113940997B (en) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 Stable preparation of bispecific antibody
CN118369117A (en) * 2021-12-28 2024-07-19 山东先声生物制药有限公司 Anti-TNFR 2 antibody pharmaceutical composition
CN120322247A (en) * 2022-12-09 2025-07-15 辛特里亚公司 Methods for treating sarcoidosis using TNFα antibodies and related compositions and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994011041A1 (en) 1992-11-19 1994-05-26 R G S.A.S. Di Rosaria Galli & C. Disposable auto-injector for prefilled syringes
DE4438360C2 (en) 1994-10-27 1999-05-20 Schott Glas Pre-fillable, low-particle, sterile disposable syringe for the injection of preparations and methods for their manufacture
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
KR102013220B1 (en) 2008-06-25 2019-08-23 에스바테크 - 어 노바티스 컴파니 엘엘씨 Stable and soluble antibodies inhibiting vegf
CN102458469B (en) * 2009-05-04 2014-12-24 艾伯维生物技术有限公司 Stable high protein concentration formulations of human anti-TNF-α antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2807190B1 (en) * 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
MX370199B (en) * 2012-02-16 2019-12-05 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions.
NZ629261A (en) 2012-03-07 2017-08-25 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SMT202000147T1 (en) 2012-09-07 2020-05-08 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
FR2995214B1 (en) 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
WO2014058389A1 (en) * 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
AU2013334740A1 (en) * 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
WO2014078866A2 (en) * 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
RU2015130100A (en) 2013-01-24 2017-03-03 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед TNF-alpha antigen binding proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN104666242B (en) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 A kind of anti-TNF Alpha antibodies preparation of stabilization and application thereof
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2600488T3 (en) * 2014-05-23 2017-02-09 Ares Trading S.A. Liquid pharmaceutical composition
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
CA2976298A1 (en) 2015-02-13 2016-08-18 Sanofi Stable liquid formulation for monoclonal antibodies
AR118191A1 (en) 2019-02-28 2021-09-22 Celltrion Inc METHODS FOR THE TREATMENT OF TNFa-RELATED DISEASES

Also Published As

Publication number Publication date
LT3479819T (en) 2024-04-25
NZ770076A (en) 2025-03-28
JOP20180125B1 (en) 2022-09-15
KR102397713B1 (en) 2022-05-13
US11951207B2 (en) 2024-04-09
CR20180599A (en) 2019-04-09
IL263630A (en) 2019-01-31
NI201800139A (en) 2019-03-25
NZ748101A (en) 2020-11-27
AU2020201249A1 (en) 2020-03-12
EP3479819A4 (en) 2020-02-26
MA45562B1 (en) 2024-05-31
DOP2018000290A (en) 2019-02-15
JOP20180125A1 (en) 2019-01-30
EP4338752A2 (en) 2024-03-20
CA3028238A1 (en) 2018-01-04
JP2022122941A (en) 2022-08-23
CL2018003662A1 (en) 2019-03-15
AU2017287743C1 (en) 2020-10-01
CA3028238C (en) 2024-01-02
TWI736643B (en) 2021-08-21
PT3479819T (en) 2024-04-15
JP7082070B2 (en) 2022-06-07
KR20180003452A (en) 2018-01-09
MA45562A (en) 2019-05-08
SG11201811320YA (en) 2019-01-30
PH12018502670A1 (en) 2019-10-07
EP3479819A1 (en) 2019-05-08
EP3479819B1 (en) 2024-01-24
KR20210042052A (en) 2021-04-16
DK3479819T5 (en) 2024-09-09
JP7405324B2 (en) 2023-12-26
WO2018004260A1 (en) 2018-01-04
MD3479819T2 (en) 2024-07-31
PE20190448A1 (en) 2019-03-29
SI3479819T1 (en) 2024-06-28
ZA201808476B (en) 2020-08-26
FI3479819T3 (en) 2024-04-17
KR20180097471A (en) 2018-08-31
AU2017287743A1 (en) 2018-11-22
SMT202400143T1 (en) 2024-05-14
HUE066142T2 (en) 2024-07-28
UA122610C2 (en) 2020-12-10
AU2020201249B2 (en) 2021-07-15
PH12018502670B1 (en) 2023-03-24
CO2018013689A2 (en) 2019-01-18
EA201892653A1 (en) 2019-05-31
GEP20217249B (en) 2021-04-26
TW201806617A (en) 2018-03-01
US20240269071A1 (en) 2024-08-15
US20240269069A1 (en) 2024-08-15
BR112018076377A2 (en) 2019-03-26
KR102229274B1 (en) 2021-03-18
CU20180154A7 (en) 2019-08-06
ES2975782T3 (en) 2024-07-15
CN109310628A (en) 2019-02-05
US20210000743A1 (en) 2021-01-07
ECSP18093651A (en) 2019-01-31
TN2018000443A1 (en) 2020-06-15
IL263630B2 (en) 2023-06-01
CU24561B1 (en) 2022-01-13
EP4338752A3 (en) 2024-04-03
PL3479819T3 (en) 2024-07-01
DK3479819T3 (en) 2024-04-15
RS65395B1 (en) 2024-04-30
AU2017287743B2 (en) 2020-01-30
HRP20240426T1 (en) 2024-06-21
JP2019525902A (en) 2019-09-12

Similar Documents

Publication Publication Date Title
PH12018502670A1 (en) Stable liquid pharmaceutical preparation
AU2014318696B2 (en) Liquid protein formulations containing organophosphates
MX2017010400A (en) Stable liquid formulation for monoclonal antibodies.
EP4438060A3 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX370207B (en) Stabilized antibody compositions.
MX2019009176A (en) Etanercept formulations stabilized with metal ions.
MX2018015272A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2018015268A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX359999B (en) Liquid stable bovine virus vaccines.
MX2018015274A (en) Anti-cd98 antibodies and antibody drug conjugates.
AR098168A1 (en) STABLE FORMULATION OF GLULISINE INSULIN
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
IN2014MU01248A (en)
CR20220322A (en) ANTI-PD-L1 ANTIBODY FORMULATIONS
MX390873B (en) VACCINE COMPOSITIONS WITH REDUCED FOAMING.
MY194758A (en) Stable liquid pharmaceutical formulation
SA520420369B1 (en) A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
UA86343U (en) Composition of marmalade "svizhist" (freshness) with envigorating properties
HK1226318A1 (en) Liquid protein formulations containing organophosphates
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
TH1701002015A (en) Vaccine composition with reduced foaming
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes